An Exploratory Evaluation of Technetium Tc 99m Tilmanocept by Intravenous (IV) Injection in Subjects With Liver Metastases From Colorectal Carcinoma Patients Using SPECT/CT Imaging Compared to FDG PET/CT Imaging
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 12 Oct 2018
At a glance
- Drugs Tc 99m tilmanocept (Primary) ; Tc 99m tilmanocept (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Liver metastases
- Focus Adverse reactions; Diagnostic use
- Sponsors Navidea Biopharmaceuticals
- 04 Oct 2018 Planned primary completion date changed from 1 Sep 2018 to 1 Dec 2018.
- 04 Oct 2018 Status changed from recruiting to active, no longer recruiting.
- 12 Jul 2018 Planned End Date changed from 1 Mar 2018 to 1 Jan 2019.